International Stem Cell Corporation to Present at American Society of Gene and Cell Therapy 16th Annual Meeting
CARLSBAD, CA--(Marketwired - May 1, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies announced that Dr. Ruslan Semechkin, VP of Research and Development, will present additional data from the primate study of the use of neuronal cells for the treatment of Parkinson's disease at the 16th Annual Meeting of American Society of Gene and Cell Therapy, May 15-18, 2013 at the Salt Palace Convention Center in Salt Lake City, UT.
The results, including more detailed analysis of the safety and functional activity of the cells, will be presented orally at the following session:
Session: Stem Cell Engineering and Therapy
Date: Thursday, May 16, 2013
Time: 2:00 PM
Room: Ballroom D
Title: Cell Replacement Therapy for Parkinson's Disease with Neuronal Cells Derived from Human Parthenogenetic Stem Cells
In addition ISCO will present two posters detailing progress in our pre-clinical metabolic liver disease program and recent achievements with our "safe" iPS cells, induced pluripotent stem cells that do not rely on viral vectors for the genetic reprogramming. The posters will be presented on Thursday, May 16, 2013 between 4:00 pm and 6:00 pm in Exhibit Hall C/D.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
